Pharma

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Gottlieb Eyes Prices, Not Lives

Gottlieb Eyes Prices, Not Lives

It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.

Ironwood strengthens leadership with two new hires

Ironwood strengthens leadership with two new hires

By

The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

By

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

How will the pharma industry fare in 2018 under Trump?

How will the pharma industry fare in 2018 under Trump?

By

The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.

The 2018 pipeline report: Aspiring assets to keep an eye on

The 2018 pipeline report: Aspiring assets to keep an eye on

By

The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

6 Corporate Pharma Sites that Offer Strong User Experiences

6 Corporate Pharma Sites that Offer Strong User Experiences

It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.

Looking Beyond Overall Survival

Looking Beyond Overall Survival

Our understanding of how cancer develops and thrives has grown.

Five things for pharma marketers to know: Tuesday, November 14, 2017

Five things for pharma marketers to know: Tuesday, November 14, 2017

By

FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

By

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Front seat to the comms evolution: Abbott's Melissa Brotz

Front seat to the comms evolution: Abbott's Melissa Brotz

By

The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.

Who's Getting Rich in Healthcare?

Who's Getting Rich in Healthcare?

Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?

Porter Novelli wins lucrative multi-year CSR brief with Johnson & Johnson

Porter Novelli wins lucrative multi-year CSR brief with Johnson & Johnson

By

Porter Novelli has been appointed to lead a new global CSR brief for pharma and consumer goods giant Johnson & Johnson, as the company faces a major reputation challenge in the US.

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

10 questions for PhRMA's CEO Stephen Ubl

10 questions for PhRMA's CEO Stephen Ubl

By

Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.

Sanofi asks the world 'How are you?' in latest corporate branding campaign

Sanofi asks the world 'How are you?' in latest corporate branding campaign

By

The Paris-based pharma company debuted a brand campaign and signature last week.

Up to 20% of pharma brands moving digital media spend to point-of-care

Up to 20% of pharma brands moving digital media spend to point-of-care

By

Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.

Drugmakers begin to up media controls, in bid to clean up digital ad supply

Drugmakers begin to up media controls, in bid to clean up digital ad supply

By

Like its consumer-products cousins, pharma marketers are exercising more discipline over online media. Will it yield similar results?

AI Drug Design Could Save Lives

AI Drug Design Could Save Lives

AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.

Ready or not, Amazon is Coming

Ready or not, Amazon is Coming

The e-giant is reportedly doing everything from starting secret labs and online pharmacies to redefining the hospital experience and democratizing health data.

Infographic | How often are drugmakers sharing clinical-trial data?

Infographic | How often are drugmakers sharing clinical-trial data?

The answer: it depends on what phase the trial is in.

New pharma CEOs to face payer, pricing challenges

New pharma CEOs to face payer, pricing challenges

By

They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.

Five things for pharma marketers to know: Tuesday, September 5, 2017

Five things for pharma marketers to know: Tuesday, September 5, 2017

By

Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis

Pharma's $6 billion annual ad spend targeted by media publishers

Pharma's $6 billion annual ad spend targeted by media publishers

By

Condé Nast, Time Inc., and Vice Media have all recently launched health content businesses.

Bill to allow imported drugs from Canada aims to create competition

Bill to allow imported drugs from Canada aims to create competition

By

The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.

Drugmakers test out Tumblr, to tap specific audiences

Drugmakers test out Tumblr, to tap specific audiences

By By

Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.

Pharma companies, now marketing high-science drugs, rely more on medical affairs

Pharma companies, now marketing high-science drugs, rely more on medical affairs

By

Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.

From diversity to pricing issues, BMS marketing chief strikes a balance

From diversity to pricing issues, BMS marketing chief strikes a balance

By

Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.

Neil Matheson leaves Huntsworth Health

Neil Matheson leaves Huntsworth Health

By

The CEO of Huntsworth's biggest and fastest-growing unit Huntsworth Health, which includes Nitrogen and Tonic Life, has departed after eight years.